Fusion proteins having mutated immunoglobulin hinge region

Details Fusion proteins having mutated immunoglobulin hinge region Fusion proteins having mutated immunoglobulin hinge region

2008-07-25

2011-11-29

Gussow, Anne M. (Department: 1643)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C424S134100

Reexamination Certificate

active

08067548

ABSTRACT:
A fusion protein having a non-immunoglobulin polypeptide having a cysteine residue proximal to the C terminal thereof, and an immunoglobulin component with a mutated hinge region is provided. The mutation comprises a point mutated site corresponding in position to the position in a native hinge region of the cysteine residue located nearest the cysteine residue of the non-Ig component. The distance from the cysteine residue of the non-immunoglobulin polypeptide and any remaining cysteine residues of the mutated hinge region is sufficient to prevent the formation of a disulphide bond therebetween.

REFERENCES:
patent: 5116964 (1992-05-01), Capon et al.
patent: 5618698 (1997-04-01), Lin
patent: 5908626 (1999-06-01), Chang et al.
patent: 5916773 (1999-06-01), Mele et al.
patent: 6096871 (2000-08-01), Presta et al.
patent: 6165476 (2000-12-01), Strom et al.
patent: 6403077 (2002-06-01), Strom et al.
patent: 6548653 (2003-04-01), Young et al.
patent: 6586398 (2003-07-01), Kinstler et al.
patent: 6660843 (2003-12-01), Feige et al.
patent: 6750334 (2004-06-01), Gray et al.
patent: 6797493 (2004-09-01), Sun et al.
patent: 6808902 (2004-10-01), Treuheit et al.
patent: 6821505 (2004-11-01), Ward
patent: 6900292 (2005-05-01), Sun et al.
patent: 6936439 (2005-08-01), Mann et al.
patent: 6987006 (2006-01-01), Fleer et al.
patent: 6989365 (2006-01-01), Fleer et al.
patent: 7030226 (2006-04-01), Sun et al.
patent: 7041478 (2006-05-01), Fleer et al.
patent: 7056701 (2006-06-01), Fleer et al.
patent: 7250493 (2007-07-01), Sun et al.
patent: 7625564 (2009-12-01), Wang et al.
patent: 2003/0044423 (2003-03-01), Gillies et al.
patent: 2004/0063912 (2004-04-01), Blumberg et al.
patent: 2004/0175824 (2004-09-01), Sun et al.
patent: 2005/0048572 (2005-03-01), Reilly et al.
patent: 2005/0124045 (2005-06-01), Sun et al.
patent: 2005/0202538 (2005-09-01), Gillies et al.
patent: 2005/0238646 (2005-10-01), Ledbetter et al.
patent: 2007/0178112 (2007-08-01), Wang et al.
patent: 2007/0269371 (2007-11-01), Krummen et al.
patent: 2008/0260746 (2008-10-01), Abderrahim et al.
patent: 2009/0297522 (2009-12-01), Wang et al.
patent: 2010/0098716 (2010-04-01), Wang et al.
patent: 2010/0099145 (2010-04-01), Wang et al.
patent: 2328490 (1999-11-01), None
patent: 464533 (1992-01-01), None
patent: WO9902709 (1999-01-01), None
patent: WO9958662 (1999-11-01), None
patent: WO9966054 (1999-12-01), None
patent: WO0103737 (2001-01-01), None
patent: WO0130320 (2001-05-01), None
patent: WO0136489 (2001-05-01), None
patent: WO0176640 (2001-10-01), None
patent: WO0181405 (2001-11-01), None
patent: WO0248194 (2002-06-01), None
patent: WO03046013 (2003-06-01), None
patent: WO03048210 (2003-06-01), None
patent: WO2004004798 (2004-01-01), None
patent: WO2004101739 (2004-11-01), None
patent: WO2005001025 (2005-01-01), None
patent: WO2005063808 (2005-07-01), None
patent: WO2005079232 (2005-09-01), None
patent: WO2006079169 (2006-08-01), None
patent: WO2007085084 (2007-08-01), None
Skolnick and Fetrow. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, 2000. vol. 18, pp. 34-39.
Burgess, Shaheen, Revera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin-binding and mitogenic activities of heparin binding (acidic fibroblast) growth factor-1 from its receptor binding activities by site directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1252.
Su, L. et al., High-level expression of human stem cell factor fused with erythropoietin mimetic peptide inEscherichia coli; Protein Expr Purif; Jun. 2006; 47(2):477-82; Epub Nov. 28, 2005.
Lee, DE et al., The prolonged half-lives of new erythropoietin derivatives via peptide addition; Biochem Biophys Res Commun; Jan. 6, 2006;339(1):380-5; Epub Nov. 14, 2005.
Dumont, JA. et al., Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway; J Aerosol Med.; 2005 Fall;18(3):294-303.
Way, JC. et al., Improvement of Fc-erythropoietin structure and pharmacokinetics by modification at a disulfide bond; Protein Eng Des Sel; Mar. 2005;18(3):111-8; Epub Apr. 8, 2005.
Bitonti, AJ. et al., Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway; Proc Natl Acad Sci USA; Jun. 29, 2004; 101(26):9763-8; Epub Jun. 21, 2004.
Dalle, B. et al., Dimeric erythropoietin fusion protein with enhanced erythropoietic activity in vitro and in vivo; Blood; Jun. 15, 2001; 97(12):3776-82.
Sytkowski, AJ. et al., An erythropoietin fusion protein comprised of identical repeating domains exhibits enhanced biological properties; J Biol Chem; Aug. 27, 1999; 274(35):24773-8.
Coscarella, A. et al., Pharmacokinetic and immunogenic behavior of three recombinant human GM-CSF-EPO hybrid proteins in cynomolgus monkeys; Mol Biotechnol; Oct. 1998; 10(2):115-22.
Amoresano, A. et al., Structural characterization and independent folding of a chimeric glycoprotein comprising granulocyte-macrophage colony stimulating factor and erythropoietin sequences; Glycobiology; Aug. 1998; 8(9): 779-90.
Coscarella, A. et al., Production of recombinant human GM-CSF-EPO hybrid proteins: in vitro biological characterization; Eur J Haematol; Oct. 1997; 59(4): 238-46.
Schriebl, K. et al., Biochemical Characterization of rhEpo-Fc Fusion Protein Expressed in CHO Cells, Protein Expression & Purification, Oct. 2006, vol. 49, No. 2, pp. 265-275.
Wang, H. et al., U.S. Appl. No. 12/162,320, Recombinant Human Epo-fc Fusion Proteins with Prolonged Half-life and Enhanced Erythropoietic Activity in Vivo, Filed Jan. 25, 2007.
Chica, R.A., et al., “Semi-rational approaches to engineering enzyme activity: combining the benefits of directed evolution and rational design”, Curr Opin Biotechnol, 2005, 16(4):378-384.
Sen, S., et al., “Developments in directed evolution for improving enzyme functions”, Appl Biochem Biotechnol, 2007, 143(3):212-223.
[U.S. Appl. No. 11/340,661] Office Action (Restriction Requirement) mailed Mar. 17, 2008 for U.S. Appl. No. 11/340,661, Wang et al., filed Jan. 27, 2006 (now US Patent No. 7625564).
[U.S. Appl. No. 11/340,661] Office Action mailed Jul. 10, 2008 for U.S. Appl. No. 11/340,661, Wang et al., filed Jan. 27, 2006 (now US Patent No. 7625564).
[U.S. Appl. No. 11/340,661] Office Action mailed Mar. 5, 2009 for U.S. Appl. No. 11/340,661, Wang et al., filed Jan. 27, 2006 (now US Patent No. 7625564).
[U.S. Appl. No. 11/340,661] Office Action mailed Jul. 22, 2009 for U.S. Appl. No. 11/340,661, Wang et al., filed Jan. 27, 2006 (now US Patent No. 7625564).
[U.S. Appl. No. 11/340,661]—Notice of Allowance mailed Aug. 13, 2009 for U.S. Appl. No. 11/340,661, Wang et al., filed Jan. 27, 2006 (now US Patent No. 7625564).
[U.S. Appl. No. 12/162,320]—Office Action (Restriction Requirement) mailed Apr. 2, 2010 for U.S. Appl. No. 12/162,320, Wang, et al., filed Jan. 25, 2007, which is a 371 of International Application No. PCT/CA2007/000107, which is a CIP of U.S. Appl. No. 11/340,661, Wang et al., filed Jan. 27, 2006 (now US Patent No. 7625564).
[U.S. Appl. No. 12/162,320]—Office Action mailed Aug. 19, 2010 for U.S. Appl. No. 12/162,320, Wang, et al., filed Jan. 25, 2007, which is a 371 of International Application No. PCT/CA2007/000107, which is a CIP of U.S. Appl. No. 11/340,661, Wang et al., filed Jan. 27, 2006 (now US Patent No. 7625564).
[U.S. Appl. No. 12/555,742]—Office Action mailed May 14, 2010 for U.S. Appl. No. 12/555,742, Wang et al., filed Dec. 10, 2008, which is a divisional of U.S. Appl. No. 11/340,661, Wang et al., filed Jan. 27, 2006 (now US Patent No. 7625564).
Terminal Disclaimer filed Feb. 21, 2011 for U.S. Appl. No. 12/162,320, Wang et al., filed Jan. 25, 2007, which is a 371 of International Application

Affiliated with

Also associated with

Rating

Fusion proteins having mutated immunoglobulin hinge region does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fusion proteins having mutated immunoglobulin hinge region, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion proteins having mutated immunoglobulin hinge region will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4286175